Turn Therapeutics closed at $9.84 on Nov 4, up 3.47%, 35.9% below its 52-week closing high. Volume of 65.7K shares was 0.69× its 20-day average (below normal).
Split-adjusted performance: -15.5% over one month, +159.3% over six months, +122.6% over one year.
Short interest was 431.2K shares at the Oct 15 settlement, up 60.4% from the prior report (3.0% of float, 4.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TTRXTurn Therapeutics | $9.84 | +3.47% | +159.3% | — | — | — | $298.8M | |
| ARCTArcturus Therapeutics Holdings | $10.54 | +10.48% | +15.4% | −89.5% | −803.8% | — | $299.6M | Compare |
| SPRYARS Pharmaceuticals | $3.08 | +0.82% | −66.9% | +114.2% | −185.2% | — | $305.8M | Compare |
| EBSEmergent Biosolutions | $6.06 | −3.12% | −33.5% | −52.4% | −29.7% | — | $310.5M | Compare |
| VOGXVogenx | $19.36 | −5.70% | — | — | — | — | $287.6M | Compare |
| FULCFulcrum Therapeutics | $3.76 | +0.53% | −47.1% | — | — | — | $287.2M | Compare |
| ENTAEnanta Pharmaceuticals | $10.73 | +3.47% | −29.6% | −21.6% | −135.8% | — | $312.5M | Compare |
| CYPHCypherpunk Technologies | $2.90 | +11.54% | +156.6% | — | — | — | $312.5M | Compare |
| BNTCBenitec Biopharma | $8.97 | +6.79% | −28.6% | — | — | — | $313.0M | Compare |
No recent articles focused on Turn Therapeutics.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
